SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
SARS-CoV-2 TREATMENT: CLINICAL INTERVENTIONS
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
REDUCTION IN INFECTIOUS SARS-COV-2 IN TREATMENT STUDY OF COVID-19 WITH MOLNUPIRAVIR (ABSTRACT
777)
Wendy P Painter
Ridgeback Biotherapeutics LP, Miami, FL, USA
MULTICENTER, OPEN-LABELED EFFICACY STUDY OF AVIFAVIR IN PATIENTS WITH COVID-19 (ABSTRACT
390)
Suzana Corritori
Viriom Incorporated, San Diego, CA, USA
CASE SERIES: TREATMENT OF COVID-19 WITH CONVALESCENT PLASMA IN B-CELL DEPLETION (ABSTRACT
391)
Arvind Gharbharan
Erasmus University Medical Center, Rotterdam, Netherlands
TREATMENT OF COVID-19 IN 22 B-CELL–DEPLETED PATIENTS (ABSTRACT
392)
Arvind Gharbharan
Erasmus University Medical Center, Rotterdam, Netherlands
REMDESIVIR VERSUS STANDARD OF CARE FOR SEVERE COVID-19 (ABSTRACT
393)
Susan Olender
Columbia University Irving Medical Center, New York, USA
COBICISTAT SYNERGIZES WITH REMDESEVIR TO SUPPRESS SARS-COV-2 REPLICATION IN VITRO (ABSTRACT
394)
Iart Luca Shytaj
Heidelberg University Hospital, Heidelberg, Germany
ACUTE KIDNEY INJURY IN PATIENTS WITH MODERATE COVID-19 TREATED WITH RDV VERSUS SOC (ABSTRACT
395)
Onyema Ogbuagu
Yale University, New Haven, CT, USA
SYMPTOM OUTCOME MEASURES FOR OUTPATIENT COVID-19 PHASE 3 TREATMENT TRIALS (ABSTRACT
396)
Kara W Chew
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
TREATMENT AND OUTCOMES OF COVID-19 IN THE US: ARE THEY DIFFERENT ACCORDING TO RACE? (ABSTRACT
397)
Essy Mozaffari
Gilead Sciences, Foster City, CA, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
